The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study

Table 2 Preoperative chemotherapy regimens employed in patients

Biomarker	DEC (n = 58)	EFC (n = 37)	VFC (n = 23)	All Patients (n = 118)
ER
negative	28	10	14	52
positive	30	27	9	66
positive rate(%)	51.7	73.0	39.1	55.9
PR
negative	31	19	12	62
positive	27	18	11	56
positive rate(%)	46.6	48.6	47.8	47.5
HER2
negative	24	16	9	49
positive	34	21	14	69
positive rate(%)	58.6	56.8	60.9	58.5
P-gp
negative	44	30	19	93
positive	14	7	4	25
positive rate(%)	24.1	18.9	17.4	21.2
MRP
negative	26	13	9	48
positive	32	24	14	70
positive rate(%)	55.2	64.9	60.9	59.3
GST-pi
negative	35	23	13	71
positive	23	14	10	47
positive rate(%)	39.7	37.8	43.5	39.8
Topo-II
negative	23	14	7	44
positive	35	23	16	74
positive rate(%)	60.3	62.2	69.6	62.7

* D docetaxel, E epirubicin, C cyclophosphamide, F 5-Fluorouracil, V vinorelbine or vincristine

ISSN: 1471-2407